Dickopf S, Buldun C, Vasic V, Georges G, Hage C, Mayer K
Biol Chem. 2022; 403(5-6):495-508.
PMID: 35073465
PMC: 9125802.
DOI: 10.1515/hsz-2021-0401.
Kuo W, Hsu H, Wu C, Chen H, Chou Y, Tsou Y
MAbs. 2018; 11(1):153-165.
PMID: 30365359
PMC: 6343809.
DOI: 10.1080/19420862.2018.1541370.
Rust A, Partridge L, Davletov B, Hautbergue G
Toxins (Basel). 2017; 9(11).
PMID: 29076988
PMC: 5705959.
DOI: 10.3390/toxins9110344.
Grinberg Y, Benhar I
Biomedicines. 2017; 5(2).
PMID: 28574434
PMC: 5489814.
DOI: 10.3390/biomedicines5020028.
Hernandez-Pedro N, Rangel-Lopez E, Vargas Felix G, Pineda B, Sotelo J
Autoimmune Dis. 2013; 2013:716813.
PMID: 24294521
PMC: 3835613.
DOI: 10.1155/2013/716813.
In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.
Guo D, Han J, Li Y, Liu Z, Lu S, Ren H
Oncol Lett. 2012; 4(2):311-318.
PMID: 22844376
PMC: 3402730.
DOI: 10.3892/ol.2012.733.
Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.
Dosio F, Brusa P, Cattel L
Toxins (Basel). 2011; 3(7):848-83.
PMID: 22069744
PMC: 3202854.
DOI: 10.3390/toxins3070848.
Targeted toxins in brain tumor therapy.
Li Y, Hall W
Toxins (Basel). 2011; 2(11):2645-62.
PMID: 22069569
PMC: 3153175.
DOI: 10.3390/toxins2112645.
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Kreitman R, Pastan I
Clin Cancer Res. 2011; 17(20):6398-405.
PMID: 22003067
PMC: 3201735.
DOI: 10.1158/1078-0432.CCR-11-0487.
Bispecific digoxigenin-binding antibodies for targeted payload delivery.
Metz S, Haas A, Daub K, Croasdale R, Stracke J, Lau W
Proc Natl Acad Sci U S A. 2011; 108(20):8194-9.
PMID: 21536919
PMC: 3100918.
DOI: 10.1073/pnas.1018565108.
Fluorescent Citrine-IgG fusion proteins produced in mammalian cells.
Haas A, von Schwerin C, Matscheko D, Brinkmann U
MAbs. 2010; 2(6):648-61.
PMID: 20724830
PMC: 3011219.
DOI: 10.4161/mabs.2.6.13179.
Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
Sarnovsky R, Tendler T, Makowski M, Kiley M, Antignani A, Traini R
Cancer Immunol Immunother. 2010; 59(5):737-46.
PMID: 20091030
PMC: 7394282.
DOI: 10.1007/s00262-009-0794-4.
A novel composite immunotoxin that suppresses rabies virus production by the infected cells.
Mareeva T, Wanjalla C, Schnell M, Sykulev Y
J Immunol Methods. 2009; 353(1-2):78-86.
PMID: 19932697
PMC: 2823984.
DOI: 10.1016/j.jim.2009.11.010.
Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
Kreitman R
Curr Pharm Des. 2009; 15(23):2652-64.
PMID: 19689336
PMC: 6321767.
DOI: 10.2174/138161209788923949.
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.
Huarte E, Cubillos-Ruiz J, Nesbeth Y, Scarlett U, Martinez D, Buckanovich R
Cancer Res. 2008; 68(18):7684-91.
PMID: 18768667
PMC: 2742361.
DOI: 10.1158/0008-5472.CAN-08-1167.
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
Onda M, Beers R, Xiang L, Nagata S, Wang Q, Pastan I
Proc Natl Acad Sci U S A. 2008; 105(32):11311-6.
PMID: 18678888
PMC: 2516223.
DOI: 10.1073/pnas.0804851105.
Pseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cells.
Hafkemeyer P, Brinkmann U, Brinkmann E, Pastan I, Blum H, Baumert T
World J Gastroenterol. 2008; 14(18):2810-7.
PMID: 18473403
PMC: 2710720.
DOI: 10.3748/wjg.14.2810.
Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.
Epel M, Carmi I, Soueid-Baumgarten S, Oh S, Bera T, Pastan I
Eur J Immunol. 2008; 38(6):1706-20.
PMID: 18446790
PMC: 2682370.
DOI: 10.1002/eji.200737524.
Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome.
Wang H, Song S, Kou G, Li B, Zhang D, Hou S
Cancer Immunol Immunother. 2007; 56(11):1775-83.
PMID: 17431617
PMC: 11030707.
DOI: 10.1007/s00262-007-0321-4.
Immunotoxins for targeted cancer therapy.
Kreitman R
AAPS J. 2006; 8(3):E532-51.
PMID: 17025272
PMC: 2761061.
DOI: 10.1208/aapsj080363.